| Patient | Higuchi Ichiyō |
|---|---|
| Date of birth | 2002-05-02 |
| Identifiers | MRN HR-NI029-SYN; SSN (made up) 000-29-5108 |
| Document date | 2026-07-20 |
| Author | Aiko Lindgren-Tanaka, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Burning on passing urine for two days. [S]
Ms. Higuchi called this morning and was seen the same day. For two days she has had burning when she passes urine, needing to go often and urgently, and a dull ache low in her abdomen. She has no fever, chills, back or flank pain, nausea or vomiting, and no vaginal discharge or itching. She has never had a urinary infection before. She has not been sexually active and is not pregnant. She admits she has been drinking little while writing for long stretches at her desk on hot days. She is in the fourteenth week of tuberculosis treatment, in the continuation phase on isoniazid and rifampin, and has taken every dose on video with the public health center; her urine is orange from rifampin, as expected. Her cough has gone and she is gaining weight. [S]
| Element | Detail |
|---|---|
| Onset | Two days ago |
| Symptoms | Burning, frequency, urgency and lower abdominal ache |
| Severity | Moderate; no fever |
| Context | Continuation phase of tuberculosis treatment on isoniazid and rifampin; drinking little |
| Associated signs and symptoms | No flank pain, fever, vomiting or vaginal discharge |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, chills or night sweats |
| Genitourinary | Positive | Dysuria, frequency and urgency for two days; urine orange from rifampin; no visible blood |
| Gastrointestinal | Positive | Dull suprapubic ache; no nausea, vomiting or abdominal pain elsewhere |
| Respiratory | Negative | No cough or sputum |
| Musculoskeletal | Negative | No back or flank pain |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Isoniazid 100 mg tablets, two tablets (200 mg) daily | 200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 2026-04-17 to 2026-10-15 | completed | S |
| Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily | 450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 2026-04-17 to 2026-10-15 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phase | Oral route | 2026-04-17 to 2026-06-11 | completed | S |
| Ethambutol 100 mg tablets, six tablets (600 mg) daily | 600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results return | Oral route | 2026-04-17 to 2026-05-22 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 2026-04-17 to 2026-10-15 | completed | S |
| Nitrofurantoin monohydrate/macrocrystals 100 mg oral capsule, one capsule twice daily with food for five days | One capsule twice daily with food for five days | Oral route | 2026-07-20 to 2026-07-24 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-20 | Body height | 148 | cm | S |
| 2026-07-20 | Body weight | 42 | kg | S |
| 2026-07-20 | Body mass index (BMI) [Ratio] | 19.2 | kg/m2 | S |
| 2026-07-20 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-07-20 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-07-20 | Heart rate | 84 | /min | S |
| 2026-07-20 | Respiratory rate | 16 | /min | S |
| 2026-07-20 | Body temperature | 37 | Cel | S |
| 2026-07-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Vital signs recorded on 2026-07-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Comfortable; temperature 37.0 °C, pulse 84, blood pressure 104/66; weight 42.0 kg |
| Abdomen | Mild suprapubic tenderness; soft; liver not enlarged or tender |
| Back | No costovertebral angle tenderness |
| Eyes | No icterus |
| Skin | No rash |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and culture | resolved | confirmed | R05.3 | S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D). |
| Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected) | active | confirmed | A15.0 | S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic. |
| Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dL | active | confirmed | E44.0 | S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty. |
| Low and irregular income from writing, with a household to support; costs of care are a barrier | active | confirmed | Z59.6 | S — Synthetic social need anchored to her documented poverty and household responsibilities. |
| Acute uncomplicated cystitis, treated with nitrofurantoin rather than a fluoroquinolone during tuberculosis treatment; resolved | active | confirmed | N30.00 | S — Synthetic intercurrent illness; not a historical claim. |
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases (2010)
Follow-up: Culture result by phone. Preventive visit in five weeks as booked. Return sooner for fever or flank pain. Next scheduled visit 2026-08-24: periodic adult preventive visit. [S]